 BioPharma Dive news delivered to your inbox Get the free daily newsletter read by industry experts Email: Select Newsletter: Daily Dive Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. M-F view sample Select Newsletter: Commercialization Weekly Every Wednesday view sample Select Newsletter: Gene Therapy Weekly Every Thursday view sample Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Sign up A valid email address is required. Please select at least one newsletter. Editors' picks Permission granted by Biogen Biogen's new Alzheimer's drug Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw. At Morgan Stanley's healthcare conference last week, executives detailed how the launch of their Alzheimer's drug has been slower than expected, due in large part to lingering questions about trial data and insurance coverage. By Jacob Bell • Sept. 0, 0000 Adeline Kon/BioPharma Dive Deep Dive Biotech M&A, while far from recent heights, is picking back up. Here are the latest deals. Swiss pharma Vifor is buying Sanifit and its kidney disease drug for $000 million upfront, while Twist Biosciences is adding drug discovery specialist Abveris in a stock-based deal. By Jacob Bell and Julia Himmel • Updated Nov. 00, 0000 